N/A N=9,707 Nasopharyngeal Streptococcus Pneumoniae Carriage
Streptococcus Pneumoniae Infections
Primary: Percentage of Participants With Carriage of Streptococcus Pneumoniae in Nasopharynx — 12.6 Percentage of Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=3,641 Prevalence of Nasopharyngeal Carriage of Streptococcus Pneumoniae in Healthy Children of 12-18 Months in 6 Cities, China
Streptococcus Pneumoniae Infections
Primary: Percentage of Participants With Nasopharyngeal Carriage of Streptococcus Pneumoniae — 12.5; 7.2; 16.6; 9.3 percentage of participants
N/A N=297 Nasopharyngeal Carriage Study in Healthy Kenyan Toddlers
Pneumococcal Disease
Primary: Prevalence of Streptococcus Pneumoniae in Nasopharynx — 76; 43; 86; 46 Participants
N/A N=8,790 Streptococcus Pneumonia: Effects of PCV13 on Pneumococcal Carriage
Nasopharyngeal Carriage of S. Pneumoniae
Primary: Nasopharngeal Colonization With PCV13 S. Pneumoniae — 20; 31; 166; 137 Participants — p=<0.05
N/A N=521 Pneumococcal Nasopharyngeal and Oropharyngeal Carriage in Adults
Preference, Patient
Primary: Prevalence — 16 Participants
N/A N=2,341 Indirect Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage
Pneumococcal Infections
Primary: Carriage Due to Any Pneumococcal Serotype Included in the Ten-valent Pneumococcal Conjugate Vaccine (PCV10) Vaccine in Older Siblings of Children Vaccinated With Infant…
Phase 3 N=1,866 Study Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization
Pneumococcal Infections
Primary: Percentage of Participants With a New Acquisition of Serotype 6A' (6A + 6C) or 19A Combined 1 Month After the Infant Series to 24 Months of Age — 20.0; 36.0 percentage…
Phase 3 N=6,177 Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A
Infections, Streptococcal · Streptococcus Pneumoniae
Primary: Person Year Rate as Regards Subjects With Culture-confirmed IPD Due to Any of the 10 Pneumococcal Vaccine Serotypes. In Children Starting Vaccination Within 7 Months of…
N/A N=6,802 Study to Assess Oropharyngeal Carriage of N. Meningitidis in South Australian School Leavers
Neisseria Meningitidis
Primary: Estimate the Difference in Carriage Prevalence of Disease Associated Genogroups of N. Meningitidis (A, B, C, W, X, Y) Between School Leavers in 2018 (Year 12 in 2017)…
Phase 2 N=120 Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants
Infections, Streptococcal
Primary: Number of Subjects With Any and Grade 3 Solicited Local Symptoms and Grade 3 Solicited Local Symptoms With Relationship to Vaccination - For Step 1/Cohort 1 Subjects…
N/A N=186 Immunity to Serotype 19A Streptococcus Pneumoniae in Children Vaccinated With PCV10
Pneumococcal Infections
Primary: Persistence of Humoral Immunity Following PCV10 Vaccination — 0.32; 0.35 micrograms per ml
Phase 3 N=443 Long-term Follow-up Study of Children Previously Primed With GSK Pneumococcal Vaccine (GSK1024850A) and of Unprimed Children
Infections, Streptococcal
Primary: Antibody Concentrations Against Vaccine Pneumococcal Serotypes — 1.24; 7.63; 4.52; 12.95 μg/mL
Phase 3 N=780 Co-administration of Pneumococcal Conjugate Vaccine With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-IPV/Hib
Infections, Streptococcal
Primary: Antibody Concentrations Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F) - Primary…
Phase 3 N=484 Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age.
Infections, Streptococcal
Primary: Number of Subjects With Anti-pneumococcal Vaccine Serotype Antibody Concentrations Equal to or Above 0.20 Microgram Per Millilitre (µg/mL). — 69; 90; 93; 94 Participants
Phase 4 N=44,618 Mass Campaigns With Fractional Dose Pneumococcal Vaccines in Sub-Saharan Africa (fPCV)
Pneumococcal Carriage
Primary: Effect of a Single Dose PCV10 Campaign in the Reduction of VT Carriage — 4.6; 8.0; 16.5 Percentage of participants
Phase 3 N=41,181 Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease
Infections, Streptococcal · Streptococcus Pneumoniae
Primary: Person Year Rate as Regards Subjects With Culture-confirmed IPD Due to Any of the 10 Pneumococcal Vaccine Serotypes. In Children Starting Vaccination Within 7 Months of…
Phase 4 N=70 Safety and Immunogenicity of Sequential Pneumococcal Immunization in Preschool Asthmatics
Asthma
Primary: Immunogenicity of Pneumococcal Vaccination — 0.05; 0.05 [µg/ml]
Phase 3 N=806 Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine
Infections, Streptococcal
Primary: Number of Subjects Reporting Rectal Temperature Above (>) 39.0 Degrees Celsius (°C) — 31; 6; 30; 13 Participants
Phase 3 N=524 Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine
Infections, Streptococcal · Streptococcus Pneumoniae Vaccines
Primary: Number of Subjects With Anti-vaccine Pneumococcal Serotypes Antibody Concentrations Greater Than or Equal to (≥) the Cut-off [Follow-up Period: Persistence Analysis in…
Phase 3 N=158 Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease
Pneumococcal Conjugate Vaccine
Primary: Geometric Mean Fold Rise (GMFR) in Serotype-Specific Pneumococcal Immunoglobulin G (IgG) From 1 Month After 13vPnC Dose 1 to 1 Month After 13vPnC Dose 2 — 0.75; 0.89…
N/A N=39 Reduction of Staph Aureus Carriage by Non-Antibiotic NOZIN® Nasal Sanitizer® Antiseptic
Infectious Disease
Primary: Treatment-associated Change in S. Aureus Colonization During a Typical 10-hour Work Day — -99.8; -13.5 Percent change in colonization — p=<0.01
Phase 3 N=2,954 Novartis Vaccine and Diagnostics Carriage Trial
N. Meningitidis Carriage
Primary: Percentages of Subjects With Carriage of Virulent Sequence Types (ST) of Neisseria Meningitidis Group B, One Month After Completion of rMenB+OMV NZ Vaccination — 8; 7…
Phase 3 N=23,738 COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine
Infections, Streptococcal
Primary: Number of Subjects With a First Episode Reported of Bacterial Community Acquired Pneumoniae (B-CAP) — 240; 304 Subjects
Phase 4 N=192 Povidone-Iodine for Nasal Decolonization
Surgical Wound Infection · Preoperative Care · Methicillin-Resistant Staphylococcus Aureus
Primary: Change in S. Aureus/MRSA Colony Forming Units (CFU) in Nasal Swab Specimen After Treatment in Patients Who Presented With a Positive for S. Aureus/MRSA…
Phase 3 N=89 Immune Response In Children Revaccinated With Pneumococcal Conjugate Vaccine
Invasive Pneumococcal Disease
Primary: Percentage of Participants Achieving a Predefined Serotype-specific Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal to ( ≥) 0.35 Micrograms Per…
Phase 3 N=172 Vaccination Course in Primed Children and Age-matched Unprimed Children With Pneumococcal Vaccine GSK1024850A
Infections, Streptococcal
Primary: Antibody Geometric Mean Concentrations (GMCs) Against the Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F in the Unprimed Group — 0.06; 0.04…
Phase 3 N=2,250 Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants
Pneumonia, Pneumococcal
Primary: Serotype-specific Geometric Mean Concentration of IgG Antibody — 4.08; 4.24; 4.58; 1.34 µg/mL
Phase 2 N=57 Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Aureus
Infections, Bacterial
Primary: Plasma Retapumulin Pharmacokinetic Parameters by Treatment at Days 1 and 3 Evaluated by Plasma AUC After Dosing — 0.8663; 0.3816; 4.2802; 2.0881 ng.h /mL
Phase 3 N=756 Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines
Infections, Streptococcal
Primary: Number of Subjects Reporting Rectal Temperature Greater Than (>) the Cut-off — 64; 20 Participants
Phase 3 N=1,112 Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.
Infections, Streptococcal
Primary: Number of Subjects With Rectal Temperature Above (>) 39.0 Degrees Celsius (°C) Post Booster Between the Synflorix-Synflorix and Prevenar-Prevenar Groups — 24; 7…